Review

cttnbp2nl (Proteintech)

Name: cttnbp2nl
Brand: Proteintech
Rating: 91 (2 reviews)

Proteintech is a verified supplier

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

Proteintech cttnbp2nl

<t>CTTNBP2NL</t> has function in thyroid cancer. (a) CTTNBP2NL was highly expressed in several cancers, including THCA. (b) PDIA3 expression was positively correlated with TMB in skin cutaneous melanoma but negatively correlated with TMB in cholangiocarcinoma, acute myeloid leukemia, lung squamous cell carcinoma, and thyroid cancer. (c) In thyroid cancer, CTTNBP2NL expression showed a strong positive correlation with the gene TEAD1, indicating a potential regulatory relationship. (d) CTTNBP2NL expression was positively correlated with immune cells in THCA, suggesting it may influence tumor development, prognosis, and treatment through immune cell interactions. ✶ P < 0.05; ✶ ✶ P < 0.01; ✶ ✶ ✶ P < 0.001. CTTNBP2NL: Cortactin-binding protein 2 N-terminal-like, TMB: Tumor mutational burden, THCA: Thyroid carcinoma, TGCT: Testicular germ cell tumors, STAD: Stomach adenocarcinoma, SKCM: Skin cutaneous melanoma, SARC: Sarcoma, READ: Rectum adenocarcinoma, PRAD: Prostate adenocarcinoma, PCPG: Pheochromocytoma and paraganglioma, PAAD: Pancreatic adenocarcinoma, OV: Ovarian serous cystadenocarcinoma, MESO: Mesothelioma, LUSC: Lung squamous cell carcinoma, LUAD: Lung adenocarcinoma, LIHC: Liver hepatocellular carcinoma, LGG: Lower-grade glioma, LAML: Acute myeloid leukemia, KIRP: Kidney renal papillary cell carcinoma, KIRC: Kidney renal clear cell carcinoma, KICH: Kidney chromophobe, HNSC: Head and neck squamous cell carcinoma, GBM: Glioblastoma multiforme, ESCA: Esophageal carcinoma, DLBC: Diffuse large B-cell lymphoma, COAD: Colon adenocarcinoma, CHOL: Cholangiocarcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, BRCA: Breast invasive carcinoma, BLCA: Bladder urothelial carcinoma, ACC: Adrenocortical carcinoma, UVM: Uveal melanoma, UCS: Uterine carcinosarcoma, UCEC: Uterine corpus endometrial carcinoma, THYM: Thymoma.

Cttnbp2nl, supplied by Proteintech, used in various techniques. Bioz Stars score: 91/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cttnbp2nl/product/Proteintech
Average 91 stars, based on 2 article reviews

cttnbp2nl - by Bioz Stars, 2026-02

91/100 stars

Images

1) Product Images from "Transcriptional enhanced associate domain factor 1 regulates cortactin-binding protein 2 N-terminal-like to control cell apoptosis in thyroid cancer"

Article Title: Transcriptional enhanced associate domain factor 1 regulates cortactin-binding protein 2 N-terminal-like to control cell apoptosis in thyroid cancer

Journal: CytoJournal

doi: 10.25259/Cytojournal_140_2024

CTTNBP2NL has function in thyroid cancer. (a) CTTNBP2NL was highly expressed in several cancers, including THCA. (b) PDIA3 expression was positively correlated with TMB in skin cutaneous melanoma but negatively correlated with TMB in cholangiocarcinoma, acute myeloid leukemia, lung squamous cell carcinoma, and thyroid cancer. (c) In thyroid cancer, CTTNBP2NL expression showed a strong positive correlation with the gene TEAD1, indicating a potential regulatory relationship. (d) CTTNBP2NL expression was positively correlated with immune cells in THCA, suggesting it may influence tumor development, prognosis, and treatment through immune cell interactions. ✶ P < 0.05; ✶ ✶ P < 0.01; ✶ ✶ ✶ P < 0.001. CTTNBP2NL: Cortactin-binding protein 2 N-terminal-like, TMB: Tumor mutational burden, THCA: Thyroid carcinoma, TGCT: Testicular germ cell tumors, STAD: Stomach adenocarcinoma, SKCM: Skin cutaneous melanoma, SARC: Sarcoma, READ: Rectum adenocarcinoma, PRAD: Prostate adenocarcinoma, PCPG: Pheochromocytoma and paraganglioma, PAAD: Pancreatic adenocarcinoma, OV: Ovarian serous cystadenocarcinoma, MESO: Mesothelioma, LUSC: Lung squamous cell carcinoma, LUAD: Lung adenocarcinoma, LIHC: Liver hepatocellular carcinoma, LGG: Lower-grade glioma, LAML: Acute myeloid leukemia, KIRP: Kidney renal papillary cell carcinoma, KIRC: Kidney renal clear cell carcinoma, KICH: Kidney chromophobe, HNSC: Head and neck squamous cell carcinoma, GBM: Glioblastoma multiforme, ESCA: Esophageal carcinoma, DLBC: Diffuse large B-cell lymphoma, COAD: Colon adenocarcinoma, CHOL: Cholangiocarcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, BRCA: Breast invasive carcinoma, BLCA: Bladder urothelial carcinoma, ACC: Adrenocortical carcinoma, UVM: Uveal melanoma, UCS: Uterine carcinosarcoma, UCEC: Uterine corpus endometrial carcinoma, THYM: Thymoma.

Figure Legend Snippet: CTTNBP2NL has function in thyroid cancer. (a) CTTNBP2NL was highly expressed in several cancers, including THCA. (b) PDIA3 expression was positively correlated with TMB in skin cutaneous melanoma but negatively correlated with TMB in cholangiocarcinoma, acute myeloid leukemia, lung squamous cell carcinoma, and thyroid cancer. (c) In thyroid cancer, CTTNBP2NL expression showed a strong positive correlation with the gene TEAD1, indicating a potential regulatory relationship. (d) CTTNBP2NL expression was positively correlated with immune cells in THCA, suggesting it may influence tumor development, prognosis, and treatment through immune cell interactions. ✶ P < 0.05; ✶ ✶ P < 0.01; ✶ ✶ ✶ P < 0.001. CTTNBP2NL: Cortactin-binding protein 2 N-terminal-like, TMB: Tumor mutational burden, THCA: Thyroid carcinoma, TGCT: Testicular germ cell tumors, STAD: Stomach adenocarcinoma, SKCM: Skin cutaneous melanoma, SARC: Sarcoma, READ: Rectum adenocarcinoma, PRAD: Prostate adenocarcinoma, PCPG: Pheochromocytoma and paraganglioma, PAAD: Pancreatic adenocarcinoma, OV: Ovarian serous cystadenocarcinoma, MESO: Mesothelioma, LUSC: Lung squamous cell carcinoma, LUAD: Lung adenocarcinoma, LIHC: Liver hepatocellular carcinoma, LGG: Lower-grade glioma, LAML: Acute myeloid leukemia, KIRP: Kidney renal papillary cell carcinoma, KIRC: Kidney renal clear cell carcinoma, KICH: Kidney chromophobe, HNSC: Head and neck squamous cell carcinoma, GBM: Glioblastoma multiforme, ESCA: Esophageal carcinoma, DLBC: Diffuse large B-cell lymphoma, COAD: Colon adenocarcinoma, CHOL: Cholangiocarcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, BRCA: Breast invasive carcinoma, BLCA: Bladder urothelial carcinoma, ACC: Adrenocortical carcinoma, UVM: Uveal melanoma, UCS: Uterine carcinosarcoma, UCEC: Uterine corpus endometrial carcinoma, THYM: Thymoma.

Techniques Used: Expressing, Binding Assay

Silencing CTTNBP2NL in TPC1 papillary thyroid carcinoma cells inhibits cell growth. (a) Silencing CTTNBP2NL in TPC1 papillary thyroid carcinoma cells led to a twofold reduction in protein levels. (b-d) This resulted in increased apoptosis and reduced cell proliferation and colony formation, as shown by flow cytometry, CCK8, and clonogenic assays. (e) Western blot detection of apoptosis marker. These findings highlight the crucial role of CTTNBP2NL in promoting cell survival and proliferation, suggesting it as a potential therapeutic target in PTC. ✶ ✶ P < 0.01; ✶ ✶ ✶ P < 0.001. CTTNBP2NL: Cortactin-binding protein 2 N-terminal-like, PTC: Papillary thyroid carcinoma.

Figure Legend Snippet: Silencing CTTNBP2NL in TPC1 papillary thyroid carcinoma cells inhibits cell growth. (a) Silencing CTTNBP2NL in TPC1 papillary thyroid carcinoma cells led to a twofold reduction in protein levels. (b-d) This resulted in increased apoptosis and reduced cell proliferation and colony formation, as shown by flow cytometry, CCK8, and clonogenic assays. (e) Western blot detection of apoptosis marker. These findings highlight the crucial role of CTTNBP2NL in promoting cell survival and proliferation, suggesting it as a potential therapeutic target in PTC. ✶ ✶ P < 0.01; ✶ ✶ ✶ P < 0.001. CTTNBP2NL: Cortactin-binding protein 2 N-terminal-like, PTC: Papillary thyroid carcinoma.

Techniques Used: Flow Cytometry, Western Blot, Marker, Binding Assay

Overexpression of CTTNBP2NL in TPC1 papillary thyroid carcinoma cells induced cell growth. (a) Overexpression of CTTNBP2NL in TPC1 papillary thyroid carcinoma cells resulted in a two-fold increase in protein levels. (b-d) Flow cytometry showed reduced apoptosis, while CCK8 and clonogenic assays demonstrated enhanced cell proliferation and colony formation. (e) Western blot detection of apoptosis marker. These findings suggest that CTTNBP2NL promotes cell growth and survival, making it a potential therapeutic target in PTC. ✶ ✶ P < 0.01; ✶ ✶ ✶ P < 0.001. CTTNBP2NL: Cortactin-binding protein 2 N-terminal-like, PTC: Papillary thyroid carcinoma.

Figure Legend Snippet: Overexpression of CTTNBP2NL in TPC1 papillary thyroid carcinoma cells induced cell growth. (a) Overexpression of CTTNBP2NL in TPC1 papillary thyroid carcinoma cells resulted in a two-fold increase in protein levels. (b-d) Flow cytometry showed reduced apoptosis, while CCK8 and clonogenic assays demonstrated enhanced cell proliferation and colony formation. (e) Western blot detection of apoptosis marker. These findings suggest that CTTNBP2NL promotes cell growth and survival, making it a potential therapeutic target in PTC. ✶ ✶ P < 0.01; ✶ ✶ ✶ P < 0.001. CTTNBP2NL: Cortactin-binding protein 2 N-terminal-like, PTC: Papillary thyroid carcinoma.

Techniques Used: Over Expression, Flow Cytometry, Western Blot, Marker, Binding Assay

TEAD1 regulates CTTNBP2NLin TPC1. (a and b) TEAD1 regulates CTTNBP2NL expression. (a and b) TEAD1 regulates CTTNBP2NL expression. (c-e) In TPC1 papillary thyroid carcinoma cells, overexpression of TEAD1 combined with CTTNBP2NL silencing led to increased cell proliferation, reduced apoptosis, and enhanced clonogenic potential compared with CTTNBP2NL silencing alone. These results suggest that TEAD1 can compensate for the loss of CTTNBP2NL, highlighting its crucial role in cell survival and proliferation. ✶ ✶ P < 0.01; ✶ ✶ ✶ P < 0.001. CTTNBP2NL: Cortactin-binding protein 2 N-terminal-like, TEAD1: Transcriptional enhanced associate domain transcription factor 1.

Figure Legend Snippet: TEAD1 regulates CTTNBP2NLin TPC1. (a and b) TEAD1 regulates CTTNBP2NL expression. (a and b) TEAD1 regulates CTTNBP2NL expression. (c-e) In TPC1 papillary thyroid carcinoma cells, overexpression of TEAD1 combined with CTTNBP2NL silencing led to increased cell proliferation, reduced apoptosis, and enhanced clonogenic potential compared with CTTNBP2NL silencing alone. These results suggest that TEAD1 can compensate for the loss of CTTNBP2NL, highlighting its crucial role in cell survival and proliferation. ✶ ✶ P < 0.01; ✶ ✶ ✶ P < 0.001. CTTNBP2NL: Cortactin-binding protein 2 N-terminal-like, TEAD1: Transcriptional enhanced associate domain transcription factor 1.

Techniques Used: Expressing, Over Expression, Binding Assay

Image Search Results

Journal: CytoJournal

Article Title: Transcriptional enhanced associate domain factor 1 regulates cortactin-binding protein 2 N-terminal-like to control cell apoptosis in thyroid cancer

doi: 10.25259/Cytojournal_140_2024

Figure Lengend Snippet: CTTNBP2NL has function in thyroid cancer. (a) CTTNBP2NL was highly expressed in several cancers, including THCA. (b) PDIA3 expression was positively correlated with TMB in skin cutaneous melanoma but negatively correlated with TMB in cholangiocarcinoma, acute myeloid leukemia, lung squamous cell carcinoma, and thyroid cancer. (c) In thyroid cancer, CTTNBP2NL expression showed a strong positive correlation with the gene TEAD1, indicating a potential regulatory relationship. (d) CTTNBP2NL expression was positively correlated with immune cells in THCA, suggesting it may influence tumor development, prognosis, and treatment through immune cell interactions. ✶ P < 0.05; ✶ ✶ P < 0.01; ✶ ✶ ✶ P < 0.001. CTTNBP2NL: Cortactin-binding protein 2 N-terminal-like, TMB: Tumor mutational burden, THCA: Thyroid carcinoma, TGCT: Testicular germ cell tumors, STAD: Stomach adenocarcinoma, SKCM: Skin cutaneous melanoma, SARC: Sarcoma, READ: Rectum adenocarcinoma, PRAD: Prostate adenocarcinoma, PCPG: Pheochromocytoma and paraganglioma, PAAD: Pancreatic adenocarcinoma, OV: Ovarian serous cystadenocarcinoma, MESO: Mesothelioma, LUSC: Lung squamous cell carcinoma, LUAD: Lung adenocarcinoma, LIHC: Liver hepatocellular carcinoma, LGG: Lower-grade glioma, LAML: Acute myeloid leukemia, KIRP: Kidney renal papillary cell carcinoma, KIRC: Kidney renal clear cell carcinoma, KICH: Kidney chromophobe, HNSC: Head and neck squamous cell carcinoma, GBM: Glioblastoma multiforme, ESCA: Esophageal carcinoma, DLBC: Diffuse large B-cell lymphoma, COAD: Colon adenocarcinoma, CHOL: Cholangiocarcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, BRCA: Breast invasive carcinoma, BLCA: Bladder urothelial carcinoma, ACC: Adrenocortical carcinoma, UVM: Uveal melanoma, UCS: Uterine carcinosarcoma, UCEC: Uterine corpus endometrial carcinoma, THYM: Thymoma.

Article Snippet: They were then incubated with primary antibodies specific to TEAD1 (diluted 1:1000, ab221367, Abcam), CTTNBP2NL (diluted 1:1000, 25523-1-AP, Proteintech), and loading control GAPDH (diluted 1:5000, ab8245, Abcam), BAX monoclonal antibody (diluted 1:1000, 50599-2-Ig, Proteintech), caspase 3/p17/p19 monoclonal antibody (diluted 1:1000,66470-2-Ig, Proteintech), P53 monoclonal antibody (diluted 1:1000, 60283-2-Ig, Proteintech), and human BCL2 polyclonal antibody (diluted 1:1000, 12789-1-AP, Proteintech).

Techniques: Expressing, Binding Assay

Journal: CytoJournal

Article Title: Transcriptional enhanced associate domain factor 1 regulates cortactin-binding protein 2 N-terminal-like to control cell apoptosis in thyroid cancer

doi: 10.25259/Cytojournal_140_2024

Figure Lengend Snippet: Silencing CTTNBP2NL in TPC1 papillary thyroid carcinoma cells inhibits cell growth. (a) Silencing CTTNBP2NL in TPC1 papillary thyroid carcinoma cells led to a twofold reduction in protein levels. (b-d) This resulted in increased apoptosis and reduced cell proliferation and colony formation, as shown by flow cytometry, CCK8, and clonogenic assays. (e) Western blot detection of apoptosis marker. These findings highlight the crucial role of CTTNBP2NL in promoting cell survival and proliferation, suggesting it as a potential therapeutic target in PTC. ✶ ✶ P < 0.01; ✶ ✶ ✶ P < 0.001. CTTNBP2NL: Cortactin-binding protein 2 N-terminal-like, PTC: Papillary thyroid carcinoma.

Techniques: Flow Cytometry, Western Blot, Marker, Binding Assay

Journal: CytoJournal

Article Title: Transcriptional enhanced associate domain factor 1 regulates cortactin-binding protein 2 N-terminal-like to control cell apoptosis in thyroid cancer

doi: 10.25259/Cytojournal_140_2024

Figure Lengend Snippet: Overexpression of CTTNBP2NL in TPC1 papillary thyroid carcinoma cells induced cell growth. (a) Overexpression of CTTNBP2NL in TPC1 papillary thyroid carcinoma cells resulted in a two-fold increase in protein levels. (b-d) Flow cytometry showed reduced apoptosis, while CCK8 and clonogenic assays demonstrated enhanced cell proliferation and colony formation. (e) Western blot detection of apoptosis marker. These findings suggest that CTTNBP2NL promotes cell growth and survival, making it a potential therapeutic target in PTC. ✶ ✶ P < 0.01; ✶ ✶ ✶ P < 0.001. CTTNBP2NL: Cortactin-binding protein 2 N-terminal-like, PTC: Papillary thyroid carcinoma.

Techniques: Over Expression, Flow Cytometry, Western Blot, Marker, Binding Assay

Journal: CytoJournal

Article Title: Transcriptional enhanced associate domain factor 1 regulates cortactin-binding protein 2 N-terminal-like to control cell apoptosis in thyroid cancer

doi: 10.25259/Cytojournal_140_2024

Figure Lengend Snippet: TEAD1 regulates CTTNBP2NLin TPC1. (a and b) TEAD1 regulates CTTNBP2NL expression. (a and b) TEAD1 regulates CTTNBP2NL expression. (c-e) In TPC1 papillary thyroid carcinoma cells, overexpression of TEAD1 combined with CTTNBP2NL silencing led to increased cell proliferation, reduced apoptosis, and enhanced clonogenic potential compared with CTTNBP2NL silencing alone. These results suggest that TEAD1 can compensate for the loss of CTTNBP2NL, highlighting its crucial role in cell survival and proliferation. ✶ ✶ P < 0.01; ✶ ✶ ✶ P < 0.001. CTTNBP2NL: Cortactin-binding protein 2 N-terminal-like, TEAD1: Transcriptional enhanced associate domain transcription factor 1.

Techniques: Expressing, Over Expression, Binding Assay

(A) Selected complex from was further analyzed. (B) MCF-7 cells were lysed and STRN was immunoprecipitated. The species-matched immunoglobulin (rabbit IgG) was added to lysates in place of antibody as a negative control condition. The resulting immunoprecipitates were analyzed by Western blot for the presence of CTTNBP2NL (top panel). The blot was stripped and re-probed for STRN (lower panel).

Journal: PLoS Computational Biology

Article Title: Recovering Protein-Protein and Domain-Domain Interactions from Aggregation of IP-MS Proteomics of Coregulator Complexes

doi: 10.1371/journal.pcbi.1002319

Figure Lengend Snippet: (A) Selected complex from was further analyzed. (B) MCF-7 cells were lysed and STRN was immunoprecipitated. The species-matched immunoglobulin (rabbit IgG) was added to lysates in place of antibody as a negative control condition. The resulting immunoprecipitates were analyzed by Western blot for the presence of CTTNBP2NL (top panel). The blot was stripped and re-probed for STRN (lower panel).

Article Snippet: Antibodies for STRN, also called Striatin, are polyclonal rabbit, and were purchased from Millipore Corp. Antibodies for CTTNBP2NL were purchased from GeneTex.

Techniques: Immunoprecipitation, Negative Control, Western Blot

Review

Structured Review

Images

1) Product Images from "Transcriptional enhanced associate domain factor 1 regulates cortactin-binding protein 2 N-terminal-like to control cell apoptosis in thyroid cancer"

Similar Products

Image Search Results